The potential of transcutaneous auricular vagus nerve stimulation for menopause

Menopause is far more than isolated hot flashes—it represents a profound shift in autonomic and neuroendocrine regulation. As ovarian hormones, especially estradiol, decline, the body's stress-response system (the HPA axis) undergoes significant changes: some women experience rising cortisol levels and flattened daily rhythms, while others show blunted cortisol reactivity and reduced feedback sensitivity.   Importantly, aging amplifies cortisol stress responses approximately three times more in women than in men, suggesting that the loss of ovarian hormones removes a protective buffer on stress physiology.  In the U.S., up to 80% of menopausal women experience vasomotor symptoms, and 40–60% report significant sleep disturbances—symptoms that carry measurable economic and quality-of-life costs.

At the same time, parasympathetic nervous system activity—reflected in vagal tone and heart rate variability (HRV)—tends to decline during the menopausal transition, creating a state of reduced stress resilience, impaired emotion regulation, and difficulty downshifting into restorative modes. This autonomic imbalance is often described as relatively higher sympathetic ("fight-or-flight") activity and reduced parasympathetic ("rest-and-digest") influence, linked to sleep difficulty, vasomotor symptoms (hot flushes and night sweats), and changes in blood pressure regulation and baroreflex function. In practical terms: if the autonomic system is persistently "revved up," the body may have a harder time downshifting into restorative states—affecting sleep depth, stress tolerance, pain processing, and daily energy.

This convergence—declining estradiol, dysregulated cortisol, and reduced vagal tone—forms a "perfect storm" that underlies the interconnected symptom clusters of menopause: sleep disruption amplifies pain sensitivity, chronic stress worsens vasomotor symptoms, and autonomic imbalance makes everything harder to regulate. This is where the vagus nerve becomes relevant. The vagus nerve is the body's major parasympathetic pathway, connecting the brain with the heart, lungs, gut, and immune system. Higher vagal tone is associated with better emotion regulation, healthier cortisol patterns, improved sleep quality, and greater stress adaptability. Transcutaneous auricular vagus nerve stimulation (taVNS)—a non-invasive method of activating vagal pathways through the outer ear—offers a promising approach to support women through this transition by targeting the autonomic system upstream of many menopausal symptoms.


What Is the Vagus Nerve—and Why Stimulate It?

The vagus nerve is the major parasympathetic nerve connecting the brain with key organs (heart, lungs, gut). It helps regulate:

  • heart rhythm and cardiovascular reflexes
  • breathing patterns and respiratory–cardiac coupling
  • inflammation-related signaling (via neuroimmune pathways)
  • digestion, gut–brain communication
  • stress reactivity and emotional regulation

Vagus nerve stimulation (VNS): When vagal pathways are engaged appropriately, many people experience a shift toward calmer physiological states—the kind associated with improved recovery, stress resilience, and sleep readiness.

What is taVNS?

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive form of VNS delivered through the outer ear (auricle), where a branch of the vagus nerve innervates specific regions. Compared with implanted VNS, taVNS is designed for accessibility and everyday use in research and wellness settings.

Why taVNS May Have Potential in Menopause

Menopause symptoms often cluster: sleep problems amplify pain sensitivity; stress worsens hot flush perception; fatigue increases anxiety; and autonomic dysregulation can make everything feel harder to control. taVNS is interesting because it targets a system that is upstream of many of these experiences: autonomic nervous system regulation.

Below are several menopause-relevant symptom domains where taVNS may be supportive, based on current autonomic and neuroimmune perspectives and adjacent clinical taVNS research:

A) Sleep and nighttime recovery
Menopause-related sleep disruption is common and is discussed in autonomic-focused menopause literature as part of hormone-related changes in autonomic and vascular physiology. Because vagal activation is associated with “downshifting” toward rest, taVNS is being explored broadly for sleep quality and arousal regulation (including in other clinical contexts where sleep disturbance and inflammation-like symptoms co-occur).

Wellness implication: taVNS may be most relevant as a pre-sleep routine or as support during periods of heightened nighttime arousal.

B) Stress load, anxiety-like symptoms, and autonomic reactivity
The autonomic system is a major mediator between perceived stress and bodily symptoms (heart rate shifts, tension, GI discomfort, temperature sensitivity). Narrative work on autonomic function across hormonal phases (e.g., menstrual cycle-related autonomic and emotional changes) reinforces that hormonal states and emotional/autonomic responses are intertwined, which conceptually supports why an autonomic-targeting approach might matter during the menopausal transition as well.

Wellness implication: taVNS paired with paced breathing is often used as a state regulation tool—a structured way to practice “turning down” physiological arousal.

C) Pain and cramping-style symptom sensitivity
Even though primary dysmenorrhea is not menopause, it provides relevant clinical evidence that taVNS can influence pain-related outcomes in hormonally modulated conditions. A randomized controlled trial in individuals with primary dysmenorrhea reports beneficial effects of taVNS, supporting the idea that auricular vagal modulation may impact pain perception and related symptoms.

Wellness implication: for menopause-associated pain (e.g., musculoskeletal discomfort, headache susceptibility, heightened pain sensitivity), taVNS is a plausible supportive option worth researching further.

D) Inflammation-like symptoms, fatigue, and “whole-body” symptom clusters
Menopause research often frames symptom burden within broader autonomic and vascular changes. In parallel, neuroimmune models of transcutaneous VNS have been proposed in conditions like breast cancer to address quality-of-life domains such as fatigue, insomnia, anxiety, and inflammation-related pathways (noting that some of this literature is emerging and may include preprints).

Wellness implication: taVNS is increasingly discussed as a tool that could support neuroimmune balance and recovery, though menopause-specific clinical trials are still an area where more direct evidence is needed.

The Potential Role of ZenoWell taVNS: Designing Modes Around Menopause Needs

ZenoWell devices are wellness-oriented taVNS products. In a menopause context, the key is not “one setting fits all,” but designing modes that match common symptom patterns—sleep disruption (SLEEP mode), stress reactivity (RELAX mode), headache sensitivity (RELIEF mode), and fluctuating daily energy (MEDIT mode).

Practical note: For menopause users, consistency often matters more than intensity. Gentle, repeatable routines tend to integrate best with sleep and stress management.

Menopause-related symptoms often reflect more than a single hormone effect—they can involve autonomic regulation, vascular responses, sleep physiology, stress reactivity, and pain processing. Because the vagus nerve is deeply involved in these systems, taVNS is a compelling, non-invasive approach that may support sleep, stress resilience, and comfort during menopause—while the field continues building menopause-specific clinical evidence.

Important note: This blog is for education and wellness information only. It is not medical advice, and it does not diagnose, treat, or cure menopause-related conditions. Always discuss symptoms and treatment options with a qualified clinician—especially if you have cardiovascular conditions, implanted devices, seizures, or are pregnant.

References:

  1. Survey of patient experience and management of vasomotor symptoms (notes VMS affect up to ~80% of menopausal women in the United States). https://journals.lww.com/menopausejournal/fulltext/2024/11000/survey_of_patient_experience_and_management_of.7.aspx
  2. Effects of Sleep Problems During Menopause. https://www.swanstudy.org/womens-health-info/effects-of-sleep-problems-during-menopause/
  3. Kızkın, Zeynep Yıldız, Rıdvan Yıldız, and Ali Veysel Özden. "Effects of Transcutaneous Auricular Vagus Nerve Stimulation in Individuals with Primary Dysmenorrhea: A Randomized Controlled Trial." Neuromodulation: Technology at the Neural Interface (2025).
  4. Lee, E. J., and M. L. Keller-Ross. "Menopause and its effects on autonomic regulation of blood pressure: Insights and perspectives." Autonomic Neuroscience (2025): 103295.
  5. Roy, Sankanika, Elettra Agordati, and Thomas DW Wilcockson. "Autonomic nervous system, cognition, and emotional valence during different phases of the menstrual cycle—a narrative review." NeuroSci 6.3 (2025): 78.
  6. Stokes, William H., et al. "Vasomotor symptoms of menopause, sympathetic activity, and blood pressure in postmenopausal females." American Journal of Physiology-Heart and Circulatory Physiology (2025).

Related Posts

Vagus Nerve Stimulation for Rheumatoid Arthritis:What Research Shows About This Emerging Treatment

Vagus nerve stimulation for rheumatoid arthritis is no longer only a laboratory idea, but the answer depends on the device. In the United States,...
發表者 ZhangLi
Oct 29 2026

World Bipolar Day: How Vagus Nerve Stimulation May Support Better Mental Health

March 30 marks World Bipolar Day and also the birthday of Vincent van Gogh. This coincidence offers more than a symbolic moment. It invites us...
發表者 Dr. XIAOJane
Oct 27 2026

研究前沿|迷走神經刺激器植入後的大型語言模型縱向症狀追蹤

簡介 植入迷走神經刺激(VNS)裝置後,患者狀況隨時間的變化通常會記錄在臨床紀錄中。這些紀錄可能描述患者在個別就診時的癲癇發作、情緒或疼痛。然而,由於紀錄格式缺乏結構,若要系統性比較數年間的變化,會相當困難。 2026 年發表於 JAMIA Open 的一項研究,評估大型語言模型(LLM)是否能從臨床紀錄中擷取症狀和嚴重程度評分,以建立患者層級的縱向變化軌跡。研究的主要重點,是評估一種臨床資訊擷取方法的表現。由此產生的變化軌跡,也初步呈現了患者之間的差異。 背景 臨床紀錄的限制 臨床紀錄必須區分「明確記載為不存在的症狀」與「未被提及的症狀」。前者表示該次就診曾進行相關評估;後者則不提供任何有關症狀狀態的資訊。紀錄中也可能提到某項持續存在的症狀,但沒有足夠細節可以判定其嚴重程度。如果把所有這類紀錄都分類為症狀不存在,就會在縱向變化估計中引入錯誤。 標準化量表可以提供一致的症狀評估,但不一定會在每次例行就診時完成。因此,研究人員檢視了是否能從現有臨床紀錄中可靠地擷取症狀,並追蹤其隨時間的變化。在使用這些紀錄進行更詳細的縱向分析之前,這是必要的方法學步驟。 方法 症狀擷取與嚴重程度分類 研究人員建立了 5 個資料集,共包括 95 名患者和 1,427 份由人工標註的臨床紀錄。訓練資料主要來自與 COVID 相關的紀錄,並加入接受 VNS 或其他手術照護患者的額外紀錄。資料以患者為單位,分為訓練集(58...
發表者 Dr. XIAOJane
Oct 23 2026

SPARC 十年歷程與超過 3.5 億美元資助:從神經定位到精準迷走神經調節

簡介 心跳、胃腸蠕動與膀胱充盈,都受到自律神經系統調節。研究人員希望透過電刺激影響神經活動,為器官功能障礙開發新的介入方式。然而,要準確地將刺激導向與疾病相關的神經纖維,並產生可重複的器官反應,仍需要回答幾個具體問題。神經會投射到哪些位置?不同個體之間的差異有多大?刺激後哪些功能會改變?又要如何及時偵測刺激目標以外的影響? 2026 年,Bhavesh Patel 及其同事在 Bioelectronic Medicine 發表綜述,整理美國國立衛生研究院(NIH)Stimulating Peripheral Activity to Relieve Conditions(SPARC)計畫的主要成果。該計畫於 2015 年啟動,向近 100 個研究項目提供超過 3.5 億美元資助,並促成 500 多篇出版物。 這篇綜述說明,神經圖譜、科技工具與開放資源如何共同支持精準神經調節。文章也指出,將基礎研究轉化為臨床應用時,仍然存在許多挑戰。 精準神經調節的主要挑戰 迷走神經將大腦與多個內部器官連接起來,是生物電子醫學的重要目標。然而,單一神經內含有走向與功能不同的神經纖維,因此刺激可能同時影響目標器官與其他生理過程。電極放置位置、神經束組織方式與刺激參數,會共同決定哪些神經纖維被招募。...
發表者 Dr. XIAOJane
Oct 23 2026

迷走神經刺激療法中,TENS貼片該貼在哪裡?

TENS 貼片該貼在哪裡才能刺激迷走神經? 如果你正在找 TENS 貼片該貼在哪裡才能刺激迷走神經,直接的回答是:不要把一般 TENS 貼片貼在脖子前方或側面。頸部包含頸動脈竇與主要神經,未經規範的電刺激可能對它們造成危險影響。對於非侵入性迷走神經刺激,最常被討論的做法是耳部刺激,也稱為 taVNS(經皮耳部迷走神經刺激)。不過,標準方形 TENS 貼片並不適合耳朵——耳朵彎曲的解剖構造需要耳夾電極或專為耳朵設計的形式。相關的耳部區域包括耳屏、耳甲艇與耳甲腔。如果你想要更簡單、更可靠、不必自行摸索的日常流程,專為耳部穿戴設計的 taVNS 裝置,例如 ZenoWell Vita 或 ZenoWell Luna,可能比硬把標準 TENS 機改裝上去更好。 主要擺放區域:耳部迷走神經刺激 如果你的目標是刺激迷走神經——無論是透過 TENS 機、耳夾,還是專用裝置——最實用且最有實證支持的做法,就是耳部迷走神經刺激,也稱為 taVNS。...
發表者 Dr. XIAOJane
Oct 22 2026

研究前沿|隨機對照研究證實,經皮耳迷走神經刺激能有效減輕肩關節鏡手術後的反彈性疼痛

簡介 神經阻滯消退時的疼痛 肩關節鏡手術後,疼痛起初可能控制良好,但隨著神經阻滯消退,疼痛可能突然加劇。這種由輕微疼痛轉為劇烈疼痛的過程稱為反彈痛,可能干擾休息與術後恢復。在阻滯作用逐漸減弱時維持穩定鎮痛,仍是圍手術期疼痛管理的重要挑戰。 2026年9月15日,Jun Zhang及其同事在《Regional Anesthesia & Pain Medicine》發表一項隨機、假刺激對照試驗,研究經皮耳部迷走神經刺激(taVNS)是否能降低肩關節鏡手術後反彈痛的發生率。 研究納入120名患者,將taVNS與假刺激,和常規麻醉及鎮痛方案進行比較。手術後24小時內,taVNS組較少出現反彈痛,部分恢復及睡眠指標也有所改善。然而,平均疼痛分數的下降幅度很小,兩組鎮痛藥使用量的差異未達統計學顯著。 背景 反彈痛管理的缺口 單次肌間溝臂叢神經阻滯(ISB)是肩部手術常用的區域鎮痛技術。局部麻醉劑作用於神經周圍,可提供約12至24小時的鎮痛,但藥效消退時,手術部位的疼痛可能迅速出現。因此,評估鎮痛策略時應單獨關注反彈痛:單日平均疼痛分數可能無法充分反映這種急劇而短暫的變化。 連續神經周圍導管及輔助藥物有助於處理這個問題,但也會增加操作、管理或藥物相關負擔。taVNS透過貼於耳部皮膚的電極刺激迷走神經耳支,為研究輔助鎮痛提供另一途徑。其給予方式不同於植入式迷走神經刺激、經皮頸部刺激及針刺式耳部神經調節。 過去研究曾探討耳部神經刺激對術後疼痛的影響,但針對單次ISB後反彈痛的證據仍有限。本試驗事先將反彈痛指定為主要終點,並在既有多模式鎮痛基礎上測試taVNS的附加效果。 方法 隨機比較與刺激方案 這項單中心試驗在中國浙江省德清縣人民醫院進行。在接受篩查的142人中,120名符合條件且安排接受肩關節鏡手術的患者按1:1隨機分組,每組60人。所有患者均完成追蹤,並納入意向治療分析。患者、結果評估者及資料分析人員均保持盲法;負責施加刺激的人員知道分組。 兩組均接受全身麻醉、一次性超聲引導ISB,以及標準化靜脈布洛芬和患者自控舒芬太尼鎮痛。ISB使用15毫升0.5%羅哌卡因。taVNS施加於左側耳甲艇,頻率30 Hz、脈衝寬度250 μs,刺激30秒、休息30秒交替進行。強度逐步提高,直到患者感到明顯麻刺感,再降低至患者確認無感覺的程度。首次治療在術前等候區開始,拔管後轉入麻醉後照護單位前持續進行。術後第1及第2天早上各進行一次2小時治療。假刺激組接受相同的電極放置及感覺閾值測試,但治療期間裝置輸出設定為零。 主要結果是手術後24小時內反彈痛的發生率。研究人員使用0至10分數字評分量表(NRS),將反彈痛定義為阻滯消退後疼痛由≤3升至≥7,且至少上升4分。阻滯消退是根據疼痛變化推定,並未透過連續感覺檢查確認。次要結果包括術後6、12、24及48小時的疼痛與舒芬太尼累積用量、恢復品質、睡眠品質及不良事件。主要結果採用卡方檢驗分析,重複測量的次要結果採用混合效應模型。恢復及睡眠分數的時間點比較進行Bonferroni校正。樣本量按主要終點估算;次要結果分析屬探索性質。 結果 主要終點與效果量...
發表者 Dr. XIAOJane
Oct 13 2026

2026 世界心理健康日:主題與有意義的行動

2026 世界心理健康日為 10 月 10 日星期六。世界衛生組織(WHO)與 World Federation for Mental Health(WFMH)公布的官方主題是「Lived experiences heard: real voices, real change」[1], [2]。今年的倡議重點,是傾聽具有心理健康相關親身經驗的人,並讓他們真正參與影響自身生活的決策、服務與政策。 個人、職場與社區都可以透過實際支持、自願參與的對話、心理健康倡議活動,以及在活動日之後持續進行的行動來參與。真正有意義的參與不需要大型活動,也不一定需要預算。2026 世界心理健康日的核心,是把「提高關注」與「傾聽」轉化為真正的參與及長期支持。 2026 世界心理健康日的主題是什麼? 2026 世界心理健康日的官方主題是「Lived...
發表者 Dr. XIAOJane
Oct 10 2026

Research Frontiers|33 萬人睡眠數據顯示:健康睡眠模式與較低失智症風險相關

中年睡眠與大腦健康 中年時期的睡眠習慣,和十多年後的失智症風險有什麼關係?一項超過 33 萬人的研究,同時分析多項睡眠特徵,包括每天的睡眠時間、頻繁失眠與白天嗜睡,評估這些特徵和日後失智症之間的關聯。 這項研究由 Tao Wei、Jie Chang 與同事進行,並於 2025 年 9 月 30 日發表在 Alzheimer's Research & Therapy。研究使用 UK Biobank 資料,參與者在納入研究時年齡為 40 至...
發表者 Dr. XIAOJane
Oct 10 2026